Correction to: Diagnostic accuracy of spleen stiffness to evaluate portal hypertension and esophageal varices in chronic liver disease: a systematic review and meta-analysis

Xing Hu¹ · Xiaojie Huang² · Jianhua Hou² · Lei Ding¹ · Chunling Su¹ · Fankun Meng¹

Published online: 18 November 2020

© The Author(s) 2020

Correction to: European Radiology

<https://doi.org/10.1007/s00330-020-07223-8>

The original version of this article, published on 24 September 2020, unfortunately contained a mistake. Reference 47 was incorrectly cited in Table 2 and Fig. 3. The corrected versions are given below.

The online version of the original article can be found at <https://doi.org/10.1007/s00330-020-07223-8>

✉ Fankun Meng
mengfankun_818@126.com

¹ Ultrasound and Functional Diagnosis Center, Beijing Youan Hospital, Capital Medical University, No. 8, Xitoutiao, Youanmenwai, Fengtai District, Beijing 100069, China

² Center for Infectious Disease, Beijing Youan Hospital, Capital Medical University, Beijing, China

Table 2 Characteristics of the studies evaluating the performance of spleen stiffness measurement (SSM) for the detection of esophageal varices

Author, year	Location	Study design	Technique	Manufacturer	The proportion of Gold standard SSM successful (%)	No. of patients	Mean age (year)	Male (%)	Mean BMI (kg/m ²)	Cirrhosis (%)	Etiology of CLD (viral, %)	Child–Pugh score (A/B/C)	Cutoff values-3 (EV)	Cutoff values-4 (HREV)
Hirooka, 2011 [23]	Japan	Prospectively	RTE	Hitachi, Japan	NR	EGD 210	62	53.8	< 25.0	NR	78.6	161/28/21	8.24	NR
Stefanescu, 2011 [24]	Romania	Prospectively	TE	FibroScan, France	85.4	EGD 122	56	56.2	26.4	100	NR	65/28/7	46.40 kPa	NR
Calvaruso, 2013 [28]	Italy	Prospective	TE	FibroScan, France	85.7	EGD 96	63	69.8	27.0	100	100	100/0/0	50.00 kPa	54.00 kPa ³
Fraquelli, 2014 [30]	Italy	Prospective	TE	FibroScan, France	83.3	EGD 110	52	59.1	23.0	23.6	100	NR	65.00 kPa	NR
Colecchia, 2012 [11]	Italy	Cross-sectional	TE	FibroScan, France	88.5	EGD 100	54	71.0	25.0	100	100	68/32/0	55.00 kPa	NR
Sharma, 2013 [29]	India	Cross-sectional	TE	FibroScan, France	89.0	EGD 174	49	88.5	24.6	100	29.9	55/99/20	40.80 kPa	NR
Stefanescu, 2015 [39]	Romania	Cross-sectional	TE	FibroScan, France	NR	EGD 90	56	55.6	26.7	100	53.3	56/32/2	NR	53.00 kPa ²
WONG, 2016 [42]	China	Cross-sectional	TE	FibroScan, France	84.1	EGD 144	58	79.2	24.4	100	100	NR	50.50 kPa	NR
Bastard, 2018 [43]	France	Cross-sectional	TE	FibroScan, France	NR	EGD 193	59	67.9	26.2	NR	NR	NR	NR	50.3 kPa ³
Takuma, 2013 [14]	Japan	Prospectively	pSWE	Siemens, Germany	95.5	EGD 340	68	52.0	23.5	100	73.8	226/93/21	3.18 m/s	3.30 m/s ²
Rizzo, 2014 [31]	Italy	Prospective	pSWE	Siemens, Germany	100	EGD 54	72	53.7	NR	100	100	A/B, 15/39	3.10 m/s	NR
Kim, 2015 [37]	Korea	Prospective	pSWE	Siemens, Germany	95.5	EGD 125	59	64.0	NR	100	60.8	84/32/8	3.16 m/s	3.40 m/s ³
Takuma, 2016 [41]	Japan	Prospective	pSWE	Siemens, Germany	96.8	EGD 60	71	56.7	23.4	100	71.6	41/18/1	3.36 m/s	3.51 m/s ⁴
Fierbinteanu-Braticievici, 2019 [47]	Romania	Prospective	pSWE	Siemens, Germany	NR	EGD 135	60	57.4	NR	100	71.1	NR	3.00 m/s	3.50 m/s ⁴
Bota, 2012 [25]	Romania	Cross-sectional	pSWE	Siemens, Germany	97.9	EGD 142	59	60.0	26.7	100	50.3	66/63/16	NR	2.55 m/s ²
Vermeiren, 2012 [26]	Germany	Cross-sectional	pSWE	Siemens, Germany	100	EGD 166	54	65.7	26.0	100	48.2	A/B + C, 90/76	NR	4.13 m/s ³
Lucchina, 2018 [44]	Italy	Cross-sectional	pSWE	Philips, Netherlands	77.8	EGD 42	NR	NR	NR	100	61.9	NR	23.87 kPa	NR
Darweesh, 2019 [46]	Egypt	Cross-sectional	pSWE	Siemens, Germany	99.0	EGD 200	55	55.5	NR	95.5	100	A/B, 144/47	3.25 m/s	NR
Peagu, 2019 [48]	Romania	Cross-sectional	pSWE	Siemens, Germany	NR	EGD 178	60	55.1	NR	100	100	NR	2.89 m/s	3.30 m/s ⁵
Giuffrè, 2019 [50]	Italy	Cross-sectional	pSWE	Philips, Netherlands	95.5	EGD 210	68	62.0	24.7	100	37.6	A/B, 179/31	31.00 kPa	46.00 kPa ⁵

Table 2 (continued)

Author, year	Location	Study design	Technique	Manufacturer	The proportion of Gold standard successful SSM (%)	No. of patients	Mean age (year)	Male (%)	Mean BMI (kg/m ²)	Cirrhosis (%)	Etiology of CLD (viral, %)	Child–Pugh score (A/B/C)	Cutoff values-3 (EV)	Cutoff values-4 (HREV)
Ye, 2012 [27]	China	Retrospective	pSWE	Siemens, Germany	NR	73	39	59.9	21.9	100	100	NR	3.16 m/s	3.39 m/s ¹
Elkrief, 2015 [35]	France	Prospective	2D-SWE	Supersonic Imagine, France	97.5	77	55	78.5	26.0	100	45.6	24/20/35	NR	32.30 kPa ⁴
Karagiannakis, 2019 [15]	Greece	Prospective	2D-SWE	Supersonic Imagine, France	90.2	64	60	50.7	NR	100	48.9	A/B, 53/18	NR	33.70 kPa ⁵
Grqurevic, 2015 [36]	Croatia	Retrospective	2D-SWE	Supersonic Imagine, France	84.9	87	63	78.2	NR	100	45.6	24/20/35	30.30 kPa	NR
Ronot, 2014 [32]	France	Prospective	MRE	Philips, Netherlands	86.0	36	56	78.0	26.0	100	42.0	7/13/16	NR	4.2 kPa ⁴
Shin, 2014 [33]	South Korea	Retrospective	MRE	GE, America	96.8	139	57	73.4	NR	100	81.3	NR	7.23 kPa	7.60 kPa ³
Morisaka, 2015 [38]	Japan	Retrospective	MRE	GE, America	NR	93	69	63.4	20.8	15.1	76.3	74/17/2	5.6 kPa	7.1 kPa ²

SSM spleen stiffness measurement, EGD esophagogastroduodenoscopy, EV esophageal varices, HREV high-risk esophageal varices, RTE real-time tissue elastography, TE transient elastography, MRE magnetic resonance elastography, 2D-SWE two-dimensional shear wave elastography, pSWE point shear wave elastography

¹ HREV were defined as any grade III EV

² HREV were defined as grade I EV with red color signs and any grade II and III EV

³ HREV were defined as any grade II and III EV

⁴ HREV were defined as any grade II and III EV or as grade I EV with red color signs or Child–Pugh class C disease

⁵ HREV were defined as esophageal varices ≥ 5 mm and/or red spots and any gastric varices

Fig. 3 Sensitivity and specificity forest plots of spleen stiffness measurement (SSM) for detecting CSPH (a), SPH (b), EV (c), and HREV (d)

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.